MTOR and acute lymphoblastic leukemia: Preclinical studies of the PI3K/mTOR inhibitor BEZ235 showed antiproliferative effects in ALL cell lines by inducing antileukemic activity when associated with glucocorticoids in in vitro and in vivo models [138].